読み込み中
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton’s tyrosine kinase (BTK) degrader, that is in Phase Phase 1a/1b clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, that is in Phase 1a/1b clinical trials to treat immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc. (Gilead), Sanofi S.A. (Sanofi), and Pfizer Inc. (Pfizer) for co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in Brisbane, California.
前日終値
$22.21
−$0.52 · -2.29%
市場前
$22.70
+$0.49 · +2.21%
10月9日 5:11 ET
日中の時刻はETです。市場データは遅延する場合があります。
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton’s tyrosine kinase (BTK) degrader, that is in Phase Phase 1a/1b clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, that is in Phase 1a/1b clinical trials to treat immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc. (Gilead), Sanofi S.A. (Sanofi), and Pfizer Inc. (Pfizer) for co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in Brisbane, California.
日中レンジ
現在 $22.21
52週レンジ
現在 $22.21
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
33
割高
センチメント
72
強気
リスク
52
やや高いリスク
モメンタム
68
上昇基調
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton’s tyrosine kinase (BTK) degrader, that is in Phase Phase 1a/1b clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, that is in Phase 1a/1b clinical trials to treat immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc. (Gilead), Sanofi S.A. (Sanofi), and Pfizer Inc. (Pfizer) for co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in Brisbane, California.
日中レンジ
現在 $22.21
52週レンジ
現在 $22.21
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 8398万 USD | 5454.9万 USD | 7698.7万 USD | 3862.7万 USD | 2975万 USD |
| 売上原価 | 1885.6万 USD | 2.22億 USD | 1.89億 USD | 1.84億 USD | 1.16億 USD |
| 粗利益 | 6512.4万 USD | −1.67億 USD | −1.12億 USD | −1.46億 USD | −8668.4万 USD |
| 研究開発 | 3.08億 USD | 2.22億 USD | 1.89億 USD | 1.84億 USD | 1.16億 USD |
| 販売・一般管理 | 5274.3万 USD | 4594.4万 USD | 4290.2万 USD | 3799.7万 USD | 3120.2万 USD |
| 営業費用 | 3.51億 USD | 4594.4万 USD | 4290.2万 USD | 3799.7万 USD | 3120.2万 USD |
| 受取利息 | 2196.9万 USD | 1972.8万 USD | 1111.5万 USD | 350.7万 USD | 82.3万 USD |
| 減価償却費と償却費 | 1885.6万 USD | 1642.8万 USD | 1365.4万 USD | 1080.8万 USD | 608.2万 USD |
| 営業利益 | −2.86億 USD | −2.13億 USD | −1.55億 USD | −1.84億 USD | −1.18億 USD |
| 純利益 | −2.64億 USD | −1.94億 USD | −1.44億 USD | −1.8億 USD | −1.17億 USD |
会社概要が更新されました 2026年10月9日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI8466.43万0.00%2.3兆 USD0.03%$379.56-0.39%
iShares Russell 2000 ETFIWM5740.78万0.07%776.97億 USD0.19%$277.57-0.05%
State Street SPDR S&P Biotech ETFXBI5122.19万0.51%101.08億 USD0.35%$149.29-0.63%
ARK Genomic Revolution ETFARKG4575.82万2.23%15.57億 USD0.75%$49.29-1.70%
Vanguard Extended Market ETFVXF2914.94万0.03%954億 USD0.05%$233.13-0.15%
iShares Biotechnology ETFIBB1699.81万0.16%104.14億 USD0.44%$200.48-1.41%
iShares Russell 2000 Growth ETFIWO1571.36万0.11%140.44億 USD0.24%$353.47-0.53%
Vanguard Russell 2000 ETFVTWO1420.83万0.08%180億 USD0.06%$112.1-0.10%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMState Street SPDR S&P Biotech ETFXBIARK Genomic Revolution ETFARKGVanguard Extended Market ETFVXFiShares Biotechnology ETFIBBiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
